Literature DB >> 16996834

Sustained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pectoris and chronic myocardial ischemia: twelve-month follow-up results.

Saskia L M A Beeres1, Jeroen J Bax, Petra Dibbets-Schneider, Marcel P M Stokkel, Willem E Fibbe, Ernst E van der Wall, Martin J Schalij, Douwe E Atsma.   

Abstract

BACKGROUND: Cell therapy has recently been introduced to treat patients with refractory angina. Because most studies have only included short-term follow-up, the effects of cell therapy over a longer period are unknown.
METHODS: In 25 patients (mean age 64 +/- 10 years, 21 men) with refractory angina, a total of 84 +/- 29 x 10(6) bone marrow-derived mononuclear cells was injected intramyocardially in regions with ischemia on technetium-99m tetrofosmin single-photon emission computed tomography. Anginal symptoms and quality of life were evaluated at baseline and at 3, 6, and 12 months. Gated single-photon emission computed tomography was performed at baseline and at 3 and 12 months to assess myocardial perfusion and left ventricular function.
RESULTS: Bone marrow cell injection was performed without any complication. At 7 months, one patient died of intracranial hemorrhage. Canadian Cardiovascular Society class improved from 3.4 +/- 0.5 to 2.3 +/- 0.6 at 3 months, 2.4 +/- 0.6 at 6 months, and 2.7 +/- 0.8 at 12 months (P < .01). Quality of life improved from 53% +/- 10% to 71% +/- 11% at 3 months, 72% +/- 14% at 6 months, and 68% +/- 14% at 12 months (P < .01). The number of segments with ischemia per patient decreased from 4.7 +/- 3.3 to 2.1 +/- 2.6 at 3 months and 1.6 +/- 2.5 at 12 months (P < .01). Left ventricular ejection fraction increased from 47% +/- 13% to 53% +/- 17% at 3 months and 51% +/- 17% at 12 months (P < .01). Regional wall motion improved from 5.9 +/- 1.7 to 6.6 +/- 2.2 mm at 3 months and 6.4 +/- 2.0 mm at 12 months (P = .01).
CONCLUSIONS: Autologous bone marrow cell injection in patients with ischemia is safe and results in a sustained beneficial effect on anginal symptoms, myocardial perfusion, and left ventricular function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996834     DOI: 10.1016/j.ahj.2006.07.018

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  18 in total

Review 1.  SPECT and PET to optimize cardiac stem cell therapy.

Authors:  Angel T Chan; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

Review 2.  Bone marrow stem cells for the treatment of ischemic heart disease: a clinical trial review.

Authors:  Eric Fuh; Todd J Brinton
Journal:  J Cardiovasc Transl Res       Date:  2009-03-17       Impact factor: 4.132

Review 3.  Intramyocardial navigation and mapping for stem cell delivery.

Authors:  Peter J Psaltis; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-23       Impact factor: 4.132

4.  The effect of bone marrow mononuclear stem cell therapy on left ventricular function and myocardial perfusion.

Authors:  Kamel Sadat; Sameer Ather; Wael Aljaroudi; Jaekyeong Heo; Ami E Iskandrian; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2013-12-31       Impact factor: 5.952

5.  Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Authors:  Emerson C Perin; James T Willerson; Carl J Pepine; Timothy D Henry; Stephen G Ellis; David X M Zhao; Guilherme V Silva; Dejian Lai; James D Thomas; Marvin W Kronenberg; A Daniel Martin; R David Anderson; Jay H Traverse; Marc S Penn; Saif Anwaruddin; Antonis K Hatzopoulos; Adrian P Gee; Doris A Taylor; Christopher R Cogle; Deirdre Smith; Lynette Westbrook; James Chen; Eileen Handberg; Rachel E Olson; Carrie Geither; Sherry Bowman; Judy Francescon; Sarah Baraniuk; Linda B Piller; Lara M Simpson; Catalin Loghin; David Aguilar; Sara Richman; Claudia Zierold; Judy Bettencourt; Shelly L Sayre; Rachel W Vojvodic; Sonia I Skarlatos; David J Gordon; Ray F Ebert; Minjung Kwak; Lemuel A Moyé; Robert D Simari
Journal:  JAMA       Date:  2012-03-24       Impact factor: 56.272

Review 6.  Concise review: therapeutic potential of adipose tissue-derived angiogenic cells.

Authors:  Krisztina Szöke; Jan E Brinchmann
Journal:  Stem Cells Transl Med       Date:  2012-09-07       Impact factor: 6.940

Review 7.  Methods to assess stem cell lineage, fate and function.

Authors:  Patricia K Nguyen; Divya Nag; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2010-09-09       Impact factor: 15.470

Review 8.  Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.

Authors:  Sheila A Fisher; Carolyn Doree; Anthony Mathur; David P Taggart; Enca Martin-Rendon
Journal:  Cochrane Database Syst Rev       Date:  2016-12-24

Review 9.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

10.  Percutaneous coronary revascularization in patients with formerly "refractory angina pectoris in end-stage coronary artery disease" - not "end-stage" after all.

Authors:  Thomas W Jax; Ansgar J Peters; Ahmed A Khattab; Matthias P Heintzen; Frank-Chris Schoebel
Journal:  BMC Cardiovasc Disord       Date:  2009-08-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.